Skip to main content

Table 4 Patient characteristics by comorbidity (overall study population)

From: Patient and disease characteristics of type-2 diabetes patients with or without chronic kidney disease: an analysis of the German DPV and DIVE databases

 

Prior stroke

Retinopathy

CAD

CKDb

Diabetic foot complications

PAD

(n = 26,270)

(n = 18,036)

(n = 30,748)

(n = 171,930)

(n = 38,765)

(n = 56,741)

Healthcare provider

 Office based in %

25.3

36.9

30.5

31.5

49.5

44.3

 Hospital based in %

74.7

63.1

69.5

68.5

50.5

55.7

Age in years

75.1 (67.8; 81.0)

71.1 (63.1; 78.0)

73.2 (65.4; 79.6)

74.5 (66.1; 80.7)

72.8 (64.3; 79.2)

73.9 (65.9; 80.1)

 < 65 years

18.1

29.9

23.7

22.4

26.7

22.6

 ≥ 65 years

81.9

70.1

76.3

77.6

73.3

77.4

Female gender in %

46.0

46.2

36.4

52.4

39.3

42.0

Weight in kg

82.0 (71.9; 94.8)

86.5 (75.0; 100.0)

85.0 (74.3; 98.0)

84.7 (73.0; 98.3)

88.0 (75.4; 103.0)

85.0 (74.0; 99.4)

Body mass index in kg/m2

29.0 (25.6; 32.9)

30.5 (26.8; 34.8)

29.4 (26.2; 33.5)

29.9 (26.3; 34.4)

30.1 (26.3; 34.6)

29.7 (26.1; 34.1)

Blood pressure

 Systolic BP in mmHg

135.0 (123.0; 146.5)

135.0 (125.0; 147.5)

130.0 (120.0; 140.0)

132.5 (120.0; 145.0)

134.0 (125.0; 145.0)

134.0 (123.0; 145.0)

  Systolic BP ≥ 140 mmHg in %

44.5

45.9

36.1

41.7

41.3

41.2

 Diastolic BP in mmHg

77.5 (70.0; 80.0)

79.0 (70.0; 80.0)

75.0 (70.0; 80.0)

78.0 (70.0; 80.0)

77.0 (70.0; 80.0)

75.5 (70.0; 80.0)

  Diastolic BP ≥ 90 mmHg in %

12.4

12.2

9.2

12.2

9.9

10.0

 AntiHT drug treatment in %

72.5

71.0

75.4

62.6

64.0

70.0

 Hypertensiona in %

85.3

84.2

85.2

79.4

79.5

82.5

Dyslipidemia in %

90.2

87.5

91.4

88.4

85.4

87.4

 LDL-C in mg/dL

104.0 (79.0; 133.0)

104.4 (80.0; 132.0)

96.0 (73.5; 123.7)

105.0 (79.3; 135.0)

104.0 (80.0; 130.0)

104.0 (79.3; 131.5)

 TC in mg/dL

177.9 (147.0; 211.5)

182 (152.7; 214.0)

168.0 (140.0; 201.1)

181.7 (150.8; 216.0)

176.0 (147.0; 208.0)

177.9 (149.0; 211.0)

 TG in mg/dL

151.0 (109.0; 215.0)

152.0 (109.0; 217.0)

151.0 (109.0; 218.0)

157.9 (113.0; 228.1)

148.9 (105.3; 210.5)

150.6 (108.0; 215.2)

 HDL-C in men in mg/dL

40.0 (34.0; 49.0)

42.0 (35.0; 50.3)

39.5 (33.0; 48.0)

40.0 (33.0, 48.5)

41.0 (34.6; 50.3)

41.3 (34.5; 50.3)

 HDL-C in women in mg/dL

46.0 (37.0; 56.1)

47.0 (38.7; 58.0)

45.0 (37.0; 55.5)

46.4 (37.5; 57.0)

48.0 (39.0; 58.5)

47.0 (38.7; 58.0)

Diabetes

 Diabetes duration in years

10.5 (5.2; 17.3)

16.1 (9.9; 23.7)

10.6 (5.1; 18.0)

10.3 (4.9; 17.2)

13.2 (7.5; 20.3)

12.0 (6.5; 19.4)

  0–5 years in %

24.1

10.6

24.8

25.5

15.9

18.9

  6–10 years in %

22.4

14.9

21.5

22.2

19.6

21.4

  > 10 years in %

53.4

74.5

53.7

52.3

64.5

59.7

 HbA1c in %

7.1 (6.3; 8.2)

7.5 (6.6; 8.6)

7.1 (6.3; 8.2)

7.1 (6.3; 8.3)

7.1 (6.3; 8.1)

7.0 (6.3; 8.1)

 HbA1c < 6.5% in %

31.7

21.7

32.2

30.5

30.7

32.5

 HbA1c < 7.0% in %

47.6

36.7

48.0

45.8

47.6

48.9

Kidney parameters

 Potassium in mmol/L

4.3 (3.9; 4.6)

4.4 (4.0; 4.7)

4.3 (4.0; 4.7)

4.3 (3.9; 4.7)

4.4 (4.1; 4.8)

4.3(4.0; 4.7)

  ≤ 4.8 mmol/L in %

85.4

81.9

83.2

81.8

79.9

81.6

  > 4.8–≤ 5.5 mmol/L in %

11.9

15.6

14.1

14.6

16.9

15.1

  > 5.5– ≤ 6.0 mmol/L in %

1.7

1.7

1.8

2.3

2.3

2.2

   > 6.0 mmol/L in %

1.1

0.7

0.9

1.3

0.9

1.0

 Urinary albumin in mg/g

  Normal (< 30 mg/g) in %

70.0

66.7

71.1

48.8

66.3

65.9

  Micro (≥ 30–300 mg/g) in %

23.1

24.9

22.5

40.8

26.4

26.5

  Macro (> 300 mg/g) in %

6.9

8.4

6.4

10.4

7.3

7.6

 Creatinine in mg/dL

1.1 (0.9; 1.4)

1.0 (0.8; 1.4)

1.1 (0.9; 1.4)

1.3 (1.0; 1.6)

1.1 (0.9 1.4)

1.1 (0.9; 1.5)

 eGFR mL/min/1.73 m2

59.4 (42.4; 76.8)

60.9 (42.8; 79.8)

59.6 (42.5; 76.0)

48.9 (36.3; 59.0)

61.5 (43.1; 81.1)

59.2 (41.7; 77.7)

  < 15

2.0

2.1

1.7

3.0

2.2

2.2

  15 to < 30 in %

8.8

9.3

9.0

12.6

8.5

9.4

  30 to < 45 in  %

17.8

16.6

17.6

25.9

16.7

17.9

  45 to < 60 in %

22.5

20.7

22.3

36.6

20.4

21.7

  60 to < 90 in %

35.9

35.7

37.3

14.1

36.1

35.4

  ≥ 90 in %

13.1

15.7

12.1

7.9

16.2

13.4

  1. Median (Q1; Q3) or percent (%)
  2. Patients with multiple comorbidities possible
  3. AntiHT antihypertensive, BP blood pressure, CAD coronary artery disease, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, PAD peripheral artery disease, TC total cholesterol, TG triglycerides
  4. aDefined as either systolic BP ≥ 140 mmHg OR diastolic BP ≥ 90 mmHg OR on antihypertensive drug treatment
  5. bDefined as eGFR < 60 mL/min/1.73 m2 OR eGFR ≥ 60 mL/min/1.73 m2 and albuminuria (≥ 30 mg/g)
Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840